Eli Lilly and Company

NYSE:LLY

Drug Manufacturers - General

Healthcare
$1,382.54 -0.95%

-$10.54 today

Market cap
$1.30T
Beta
0.52
P/E (TTM)
39.0
EPS (TTM)
$28.26
Dividend yield
0.59%
52W Low $623.78High $1,182.73

Volume 2.58M

Average 3.19M

LLY Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Eli Lilly and CompanyNYSE: LLY

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development grows, but more slowly than its trailing trend

Q2 FY2026 research & development of $3.82B rose 14.5% year over year, behind the +23.4% change in trailing-twelve-month research & development. Sequentially, it rose 8.8% from the prior quarter. Over 3 fiscal years it compounded at +22.9% a year.

Context

  • Research & development amounted to 20.5% of revenue in FY2025, down 3.9 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +14.5% toward the trailing-twelve-month pace of +23.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$3.82B+8.8% QoQ
Last fiscal yearDec 2025
$13.34B+21.3% YoY
LTMJun 2026
$14.6B+23.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.5%——
1 year+21.3%——
3-year CAGR+22.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
13.34B USD
Year-over-year change
+21.3%
4-year CAGR
+17.8%

Research & Development vs competitors

How LLY compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +23.4% is the 3rd highest of 10, against a peer median of +7.0%.
  • Research & development amounts to 18.3% of revenue for LLY, versus a peer median of 17.6%.
LLY Competitors
Research & Development for LLY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 58.11B DKK+28.3%+29.3%17.6%
MRKMerck & Co., Inc.LTM Jun 2026$28.35B USD+65.7%-2.6%42.7%
JNJJohnson & JohnsonLTM Sep 2026$16.08B USD+2.4%+1.2%16.2%
AZNAstraZeneca PLCLTM Sep 2026$15.01B USD-0.3%+13.4%24.1%
LLYEli Lilly and CompanyLTM Jun 2026$14.6B USD+23.4%+22.9%18.3%
NVSNovartis AGLTM Jun 2026$11.28B USD+9.2%+5.4%20.3%
PFEPfizer Inc.LTM Jun 2026$11.05B USD+7.0%-3.0%17.3%
ABBVAbbVie Inc.LTM Sep 2026$9.96B USD-25.0%+11.8%15.1%
SNYSanofiLTM Jun 2026€8.11B EUR+5.4%+6.5%16.6%
AMGNAmgen Inc.LTM Jun 2026$7.64B USD+19.3%+16.3%20.0%
Peer median (excluding LLY) —+7.0%+6.5%17.6%

Competitors are the stored peer set for LLY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue28.32B28.54B34.12B45.04B65.18B
Cost of Revenue7.31B6.63B7.08B8.42B11.05B
Gross Profit21.01B21.91B27.04B36.63B54.13B
Gross Margin74.2%76.8%79.2%81.3%83.0%
Research & Development6.93B7.19B9.31B10.99B13.34B
Selling, General & Admin6.14B6.07B6.94B8.59B11.09B
Operating Expenses13.07B13.26B16.25B19.59B24.43B
Depreciation & Amortization1.55B1.52B1.53B1.77B2B
EBITDA8.04B8.66B8.57B18.81B31.69B
EBITDA Margin28.4%30.3%25.1%41.8%48.6%
Operating Income7.93B8.65B10.79B17.04B29.7B
Operating Margin28.0%30.3%31.6%37.8%45.6%
Interest Income25.4M62.8M173.6M175.2M153.3M
Interest Expense339.8M331.6M485.9M780.6M795.3M
Other Income / Expenses(1.78B)(1.85B)(4.23B)(4.36B)(3.97B)
Income Before Tax6.16B6.81B6.55B12.68B25.73B
Pre-Tax Margin21.7%23.8%19.2%28.2%39.5%
Income Tax Expense573.8M561.6M1.31B2.09B5.09B
Net Income5.58B6.24B5.24B10.59B20.64B
Net Margin19.7%21.9%15.4%23.5%31.7%
EPS (Basic)5.856.575.8311.7623.07
EPS (Diluted)5.856.575.8011.7122.95
Weighted Avg Shares953.65M950.18M899.38M900.61M898M
Weighted Avg Shares (Diluted)953.65M950.18M903.28M904.06M898M

Eli Lilly and Company

NYSE:LLY

Intrinsic Alpha fair value

Locked

Current Price

$1,382.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.